TrialCritical care medicine2022

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).

Julien Carvelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.